The results presented here suggest that actin/salt-resistant and hyperactive variants of human DNase I, previously shown to have improved activity in vitro and in the digestion of mucus from cystic fibrosis patients [31], provide greater protection than the wild-type DNase I and could be considered as a potential therapeutic approach. Here, DNASE1 is linked to cystic fibrosis.